(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 8.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.77%.
Veracyte's revenue in 2025 is $495,141,000.On average, 15 Wall Street analysts forecast VCYT's revenue for 2025 to be $40,931,661,779, with the lowest VCYT revenue forecast at $38,775,200,340, and the highest VCYT revenue forecast at $42,314,231,815. On average, 15 Wall Street analysts forecast VCYT's revenue for 2026 to be $45,401,892,513, with the lowest VCYT revenue forecast at $41,955,348,570, and the highest VCYT revenue forecast at $48,182,842,419.
In 2027, VCYT is forecast to generate $50,737,711,690 in revenue, with the lowest revenue forecast at $45,295,176,129 and the highest revenue forecast at $55,171,579,804.